IP Library Granted Patent US 11,371,042
Granted Patent B2
US 11,371,042 · App. 16/407,560 · Granted Jun 28, 2022

Expression vector production and high-throughput cell screening

Inventors: Allan Bradley (Cambridge, GB); E-Chiang Lee (Cambridge, GB); Qi Liang (Cambridge, GB); Hui Liu (Cambridge, GB); Andrew Wood (Cambridge, GB); Vivian Wong (Cambridge, GB)
Assignee: Kymab Limited
C12N15/1082C07K16/00C12N15/10C12N15/1086C12N15/1096C12N15/85C07K2317/14C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,371,042
App. No.
16/407,560
Granted
Jun 28, 2022
Kind
B2
Abstract

The present invention relates inter alia to expression vector production as well as application to the production of host cells for protein repertoire expression and high-throughput screening. The invention also relates to primers useful for PCR amplification of nucleotide sequences encoding human antibody variable domains.

Claims (74)

1. A kit comprising isolated PCR primers, wherein:

(a) a first isolated PCR primer copies a VH gene segment and comprises a sequence selected from SEQ ID NOs: 1-5 and 7-17,

(b) a second isolated PCR primer copies a Vλ gene segment and comprises SEQ ID NO: 30, and

(c) a further at least three isolated PCR primers which copy Vκ gene segments and comprise at least 3 sequences selected from SEQ ID NOs: 18, 20-23, 25 and 26;

wherein any of the first, second or further at least three isolated PCR primers comprise at least one nucleic acid sequence tag.

2. The kit according to claim 1 , wherein the first isolated PCR primer copies a VH segment and comprises SEQ ID NO: 9, and wherein the second isolated PCR primer copies a Vλ, gene segment and comprises SEQ ID NO: 30.

3. The kit according to claim 1 , wherein the kit comprises further isolated PCR primers, wherein the further isolated PCR primers copy VH and Vκ gene segments, and wherein each of the isolated PCR primers comprises a sequence selected from SEQ ID NOs: 9, 18, 20-23, 25, and 26.

4. The kit according to claim 1 , wherein the kit comprises further isolated PCR primers, wherein the further isolated PCR primers copy VH, Vκ and Vλ, gene segments and each of the isolated PCR primers comprises a sequence selected from SEQ ID NOs: 9, 18, 20-23, 25, 26, and 30, such that each of the sequences of SEQ ID NOs: 9, 18, 20-23, 25, 26, and 30 is present in the mixture.

5. The kit according to claim 1 , wherein the kit further comprises at least one further isolated PCR primer comprising a sequence, wherein the sequence comprises:

a. an antibody heavy chain constant region sequence;

b. an antibody kappa chain constant region sequence; or

c. an antibody lambda chain constant region sequence.

6. The kit according to claim 1 , wherein the kit comprises one or more further isolated PCR primer(s) independently selected from:

a. an antibody heavy chain constant region sequence of SEQ ID NO: 48;

b. an antibody heavy chain constant region sequence of SEQ ID NO: 49;

c. an antibody kappa chain constant region sequence of SEQ ID NO: 50;

d. an antibody kappa chain constant region sequence of SEQ ID NO: 51; and

e. an antibody lambda chain constant region sequence of SEQ ID NO: 52.

7. The kit according to claim 1 , wherein the nucleic acid sequence of the at least one tag comprises a fragment of the human cytomegalovirus promoter at least 15 nucleotides in length.

8. The kit according to claim 1 , wherein the nucleic acid sequence of the tag comprises a polyA sequence.

9. The kit according to claim 1 , comprising a PCR primer mixture comprising the first and second isolated PCR primers.

10. A kit comprising at least a first, second, third and fourth isolated PCR primers, wherein:

a. the first isolated PCR primer copies a VH gene segment and comprises a sequence selected from SEQ ID NOs: 1-5 and 7-17; and

b. each of the second, third and fourth isolated PCR primers copy Vκ gene segments and each of the second, third and fourth isolated PCR primers comprises a sequence selected from SEQ ID NOs: 18, 20-23, 25 and 26, and

wherein any of the first, second, third or fourth isolated PCR primers comprise at least one nucleic acid sequence tag.

11. The kit according to claim 10 ,

comprising a further isolated PCR primer, wherein the further isolated primer copies a Vλ, gene segment and comprises SEQ ID NO: 30.

12. The kit according to claim 10 , wherein the kit further comprises at least one further isolated PCR primer comprising a sequence, wherein the sequence is comprised by:

a. an antibody heavy chain constant region sequence;

b. an antibody kappa chain constant region sequence; or

c. an antibody lambda chain constant region sequence.

13. The kit according to claim 10 , wherein the kit comprises one or more further isolated PCR primer(s) independently selected from:

a. an antibody heavy chain constant region sequence of SEQ ID NO: 48;

b. an antibody heavy chain constant region sequence of SEQ ID NO: 49;

c. an antibody kappa chain constant region sequence of SEQ ID NO: 50;

d. an antibody kappa chain constant region sequence of SEQ ID NO: 51; and

e. an antibody lambda chain constant region sequence of SEQ ID NO: 52.

14. A kit comprising at least a first isolated PCR primer and a different second isolated PCR primer, wherein the first isolated PCR primer copies a VH gene segment and comprises, from 5′ to 3′:

1) at least one nucleic acid sequence tag, and

2) a sequence selected from SEQ ID NOs: 1-17; and

the second isolated PCR primer copies a Vκ or Vλ, gene segment and comprises, from 5′ to 3′:

1) at least one nucleic acid sequence tag, and

2) a sequence selected from SEQ ID NOs: 18-47,

wherein the kit further comprises:

a. at least 3 further isolated PCR primers, wherein the at least 3 further isolated PCR primers copy VH gene segments, and wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-17;

b. at least 3 further isolated PCR primers, wherein the at least 3 further isolated PCR primers copy Vκ gene segments, and wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 18-26;

c. at least 3 further isolated PCR primers, wherein the at least 3 further isolated PCR primers copy Vλ, gene segments, and wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 27-47;

d. at least 3 further isolated PCR primers, wherein the at least 3 further isolated PCR primers copy VH and Vκ gene segments, and wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-26;

e. at least 3 further isolated PCR primers, wherein the at least 3 further isolated PCR primers copy VH and Vλ, gene segments, and wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-17 and 27-47;

f. at least 3 further isolated PCR primers, wherein the at least 3 further isolated PCR primers copy VH, Vκ and Vκ gene segments, and wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-47;

g. at least 3 further isolated PCR primers which copy VH gene segments and at least 3 further isolated PCR primers which copy Vκ gene segments, wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-26;

h. at least 3 further isolated PCR primers which copy VH gene segments and at least 3 further isolated PCR primers which copy Vλ, gene segments, wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-17 and 27-47; or

i. at least 3 further isolated PCR primers which copy VH gene segments, at least 3 further isolated PCR primers which copy Vκ gene segments, and at least 3 isolated PCR primers which copy Vλ, gene segments, wherein each further isolated PCR primer comprises a sequence selected from SEQ ID NOs: 1-47.

15. The kit according to claim 14 , wherein the kit further comprises at least one further isolated PCR primer comprising a sequence, wherein the sequence is comprised by:

a. an antibody heavy chain constant region sequence;

b. an antibody kappa chain constant region sequence; or

c. an antibody lambda chain constant region sequence.

16. The kit according to claim 14 , wherein the kit comprises one or more further isolated PCR primer(s) independently selected from:

a. an antibody heavy chain constant region sequence of SEQ ID NO: 48;

b. an antibody heavy chain constant region sequence of SEQ ID NO: 49;

c. an antibody kappa chain constant region sequence of SEQ ID NO: 50;

d. an antibody kappa chain constant region sequence of SEQ ID NO: 51; and

e. an antibody lambda chain constant region sequence of SEQ ID NO: 52.

17. A kit comprising a PCR primer mixture comprising at least a first isolated PCR primer and a second isolated PCR primer and a third isolated PCR primer, wherein the at least first, second and third isolated PCR primers are a) different, b) each comprise at least one nucleic acid sequence tag, and c) each PCR primer comprises a sequence selected from SEQ ID NOs: 18-26.

18. The kit according to claim 17 , wherein the kit further comprises at least one further isolated PCR primer comprising a sequence, wherein the sequence is comprised by:

a. an antibody heavy chain constant region sequence;

b. an antibody kappa chain constant region sequence; or

c. an antibody lambda chain constant region sequence.

19. The kit according to claim 17 , wherein the kit comprises one or more further isolated PCR primer(s) independently selected from:

a. an antibody heavy chain constant region sequence of SEQ ID NO: 48;

b. an antibody heavy chain constant region sequence of SEQ ID NO: 49;

c. an antibody kappa chain constant region sequence of SEQ ID NO: 50;

d. an antibody kappa chain constant region sequence of SEQ ID NO: 51; and

e. an antibody lambda chain constant region sequence of SEQ ID NO: 52.

Assignments (2)
LICENSE Recorded Jul 14, 2020
From: KYMAB LIMITED
To: LIFEARC
Reel/Frame 053200/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2019
From: BRADLEY, ALLAN; LEE, E-CHIANG; LIANG, QI; LIU, HUI; WOOD, ANDREW; WONG, VIVIAN
To: KYMAB LIMITED
Reel/Frame 049133/0227 →
Priority Claims (1)
GB 1316644 · Sep 19, 2013 · national
Continuity (2)
Division 14917236
Related Publication 20190300876A1 · Oct 3, 2019